IMB Dx, Inc. (KOSDAQ:461030)

IMB Dx Revenue

IMB Dx had revenue of 1.51B KRW in the quarter ending June 30, 2026, a decrease of -0.03%. This brings the company's total for the last twelve months to 5.60B, up 46.12% year-over-year. In the year 2025, IMB Dx had annual revenue of 5.33B with 56.40% growth. That makes IMB Dx the 40,545th largest company in the world by revenue and 2,506th in South Korea.

• Revenue (ttm): 5.60B
• Revenue Growth: +46.12%
• P/S Ratio: 6.00
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 34.27B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Genetic Analysis Services and Medical Research Services 2.39B 70.2%
• Genome Analysis Software Product 964.83M 28.3%
• Genome Analysis Software Merchandise 51.13M 1.5%

By Geography

• South Korea 2.11B 61.8%
• Overseas 1.30B 38.2%

Fiscal year ended Dec 31, 2024 See the full IMB Dx breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	5.33B	1.92B	56.40%
Dec 31, 2024	3.41B	-619.97M	-15.40%
Dec 31, 2023	4.03B	1.40B	53.42%
Dec 31, 2022	2.62B	1.39B	113.34%
Dec 31, 2021	1.23B	-	-

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 1, 2026

Data Sources Report a data error